Fri, 15 Jan 2021 12:00:00 EST Post-marketing Evaluation of Mudan Granule Intervention on Type 2 Diabetic Peripheral Neuropathy Condition: Diabetic Peripheral Neuropathy Type 2 Interventions: Drug: Mudan granule; Drug: Placebo Sponsors: Fengmei Lian; Peking Union Medical College Hospital; Beijing Hospital; Affiliated Hospital of Liaoning University of Traditional Chinese Medicine; Affiliated Hospital of Qingdao University; Chengdu University of Traditional Chinese Medicine; The Fourth People's Hospital of Chongqing; Zhengzhou Yihe Hospital Affiliated to Henan University; Zhu Xianyi Memorial Hospital of Tianjin Medical University; The Third Hospital of Xi'an; Huashan Hospital; Gansu Provincial People's Hospital; Shenzhen Hospital of Guangzhou University of Traditional Chinese Medicine; Affiliated Hospital of Changchun University of Chinese Medicine Not yet recruiting
Fri, 15 Jan 2021 12:00:00 EST Surgical Innovation for Diabetes Treatment 2 Conditions: Enteroendocrine Physiological Changes in Superobese Patients Submitted to Two Different Bariatric Procedures; Determine Whether BPD With DS or SADI-S as Primary or Revisional Surgery is Superior Than the Other as First Choice for the Superobese; Determine Whether or Not Revision Surgery is as Effective as Primary Surgery and Understand the Physiological Mechanisms Inherent in These Putative Differences Interventions: Procedure: Single anastomosis duodeno-ileal bypass; Procedure: Biliopancreatic diversion with duodenal switch; Procedure: SADI-S as a revisional procedure; Procedure: BPD-DS as a revisional procedure Sponsors: Hospital de Sao Sebastiao; Instituto de Ciências Biomédicas Abel Salazar; The Novo Nordisk Foundation Center for Basic Metabolic Research Recruiting
Fri, 15 Jan 2021 12:00:00 EST The Use of Faster Acting Aspart in Type 1 Diabetes Patients Conditions: Type 1 Diabetes; Insulin; Time in Range Intervention: Sponsors: University Hospital, Antwerp; Universitaire Ziekenhuizen Leuven Completed
Thu, 14 Jan 2021 12:00:00 EST Effects of COVID-19 on Endothelium in HIV-Positive Patients in Sub-Saharan Africa Conditions: Covid19; Hiv; ART Interventions: Biological: COVID-19; Biological: HIV; Drug: ART Sponsors: Medical University of Graz; University of Olso; Kristiania University College; Walter Sisulu University; Lagos State University; Management Sciences for Health Recruiting
Thu, 14 Jan 2021 12:00:00 EST Elements Vital to Treat Obesity Study Condition: Obesity Interventions: Behavioral: APP; Behavioral: DPP Sponsors: Northwestern University; Washington University School of Medicine Not yet recruiting
FDA (Food and Drug Administration) press releases. FDA makes sure of the safety of all medicines which can be injected, breathed in, rubbed in and swallowed, in the United States of America.
Fri, 15 Jan 2021 17:36:05 EST Federal judge enters consent decree against Washington state juice processor The U.S. District Court for the Eastern District of Washington entered a consent decree between the FDA and Valley Processing, Inc., to stop distributing adulterated juice products until the company complies with the Federal Food, Drug, and Cosmetic Act (FD&C Act)
Thu, 14 Jan 2021 13:57:37 EST CBP, FDA Seize Counterfeit, Unauthorized E-Cigarettes U.S. Customs and Border Protection officers at the Dallas Fort Worth International Airport working in conjunction with agents from the U.S. Food and Drug Administration announced today that they have seized over 33,681 units of e-cigarettes with a Manufacturer’s Suggested Retail Price of $719,453.
Wed, 13 Jan 2021 15:18:38 EST FDA Releases Artificial Intelligence/Machine Learning Action Plan FDA has released the Artificial Intelligence/Machine Learning- Based Software as a Medical Device Action Plan which outlines FDA’s next steps towards advancing practical oversight for these issues.
Fri, 08 Jan 2021 15:28:21 EST FDA Issues Alert Regarding SARS-CoV-2 Viral Mutation to Health Care Providers and Clinical Laboratory Staff FDA is alerting clinical laboratory staff and health care providers that it is monitoring the impact of viral mutations, including the variant from the United Kingdom, the B.1.1.7 variant, on authorized SARS-CoV-2 molecular tests, and that false negative results can occur with any molecular test.
